search
Back to results

Glutathione Metabolism in Adolescents With Type 1 Diabetes - Study B

Primary Purpose

Diabetes Mellitus, Type 1

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Antioxidant supplement
Diabetes treatment
Regular Insulin
Sponsored by
Nemours Children's Clinic
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Diabetes Mellitus, Type 1 focused on measuring Glutathione

Eligibility Criteria

12 Years - 21 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Type 1 diabetes, using usual criteria such as: glycosuria, hyperglycemia prior to treatment
  • BMI <25 kg/m2
  • Age 12-21
  • HbA1c>7.5%
  • No evidence of diabetic complications
  • Written informed consent from parents or legal guardian, and assent from patient

Exclusion Criteria:

  • Presence of significant anemia (hemoglobin <11g/dL)
  • Presence of intercurrent illness such as infection
  • Presence of chronic disease such as other endocrine deficiency, chronic respiratory or cardiac disease
  • Chronic use of medication other than insulin
  • Use of vitamin or mineral supplements within 2 weeks of study

Sites / Locations

  • Nemours Children's Clinic

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Antioxidant Supplement

Placebo

Arm Description

Vitamin C 250 mg; beta-carotene 6 mg; vitamin E 30 mg; selenium 100 mcg; zinc 20 mg

Outcomes

Primary Outcome Measures

Glutathione Concentration
While at near normoglycemia

Secondary Outcome Measures

Plasma Protein Bound 3-nitrotyrosine
Marker of oxidative stress

Full Information

First Posted
March 6, 2009
Last Updated
April 24, 2023
Sponsor
Nemours Children's Clinic
Collaborators
Juvenile Diabetes Research Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT00858273
Brief Title
Glutathione Metabolism in Adolescents With Type 1 Diabetes - Study B
Official Title
Regulation of Glutathione Homeostasis in Adolescents With Type 1 Diabetes - Study B
Study Type
Interventional

2. Study Status

Record Verification Date
May 2012
Overall Recruitment Status
Completed
Study Start Date
March 2008 (undefined)
Primary Completion Date
March 2011 (Actual)
Study Completion Date
August 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Nemours Children's Clinic
Collaborators
Juvenile Diabetes Research Foundation

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Glutathione is normally present at high levels in the blood and plays an important role in the body's defense against oxidative stress, that is, against the damage caused to the body by several reactive oxygen species produced by the metabolism of most nutrients, including glucose. Glutathione is a small peptide made from 3 amino acids, glutamate, cysteine, and glycine. This study is looking at how blood sugar levels may affect the way glutathione is made and used by the body. Since glutathione is continuously synthesized and broken down, the amount of glutathione present in the blood depends on the balance between its rate of synthesis and its rate of use. In earlier studies, we found that in poorly controlled diabetic teenagers, glutathione was low, not because it was not produced fast enough, but because it was used at an excessive rate. In this study, we want to find out whether improving blood sugar control will increase glutathione levels, and, if so, how long this will take. We also hope to find out if oral supplementation with a mixture of several antioxidant vitamins and minerals will increase glutathione levels more than taking a placebo.
Detailed Description
Forty adolescents with T1D will undergo a measurement of blood glutathione concentration and markers of oxidative stress (plasma protein-bound 3-nitrotyrosine, and urinary 8OH-2-dG, and F2-isoprostane excretion, markers of oxidative damage to protein, DNA and lipids, respectively) while at near normoglycemia, on two separate occasions: first, when in poor glucose control (HbA1c>7.5%); and secondly, after 3 to 9 months months of improved blood glucose control, along with the administration of either a placebo, or a mixture of antioxidant minerals and vitamins based on a randomization scheme. Between the two metabolic study days, patients will receive the same intensified diabetes regimen consisting of education and counseling, home blood glucose monitoring, multiple daily insulin injections (MDI), diet plan, and frequent phone contact with a certified diabetes educator.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 1
Keywords
Glutathione

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
41 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Antioxidant Supplement
Arm Type
Active Comparator
Arm Description
Vitamin C 250 mg; beta-carotene 6 mg; vitamin E 30 mg; selenium 100 mcg; zinc 20 mg
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Dietary Supplement
Intervention Name(s)
Antioxidant supplement
Intervention Description
1 capsule daily with dinner
Intervention Type
Other
Intervention Name(s)
Diabetes treatment
Intervention Description
Intensification of diabetes treatment regimen, including education and counseling, home blood glucose monitoring, multiple daily insulin injections (MDI), diet plan, and frequent phone contact with a certified diabetes educator
Intervention Type
Drug
Intervention Name(s)
Regular Insulin
Intervention Description
Regular Insulin, IV, to maintain blood glucose in normoglycemic range (70-140) during metabolic study
Primary Outcome Measure Information:
Title
Glutathione Concentration
Description
While at near normoglycemia
Time Frame
After 3-9 months of improved blood glucose control (HbA1c decrease of >0.5%)
Secondary Outcome Measure Information:
Title
Plasma Protein Bound 3-nitrotyrosine
Description
Marker of oxidative stress
Time Frame
After 3-9 months of improved blood glucose control (HbA1c decrease of >0.5%)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Type 1 diabetes, using usual criteria such as: glycosuria, hyperglycemia prior to treatment BMI <25 kg/m2 Age 12-21 HbA1c>7.5% No evidence of diabetic complications Written informed consent from parents or legal guardian, and assent from patient Exclusion Criteria: Presence of significant anemia (hemoglobin <11g/dL) Presence of intercurrent illness such as infection Presence of chronic disease such as other endocrine deficiency, chronic respiratory or cardiac disease Chronic use of medication other than insulin Use of vitamin or mineral supplements within 2 weeks of study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dominique Darmaun, MD, PhD
Organizational Affiliation
Nemours Children's Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Nemours Children's Clinic
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32207
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Glutathione Metabolism in Adolescents With Type 1 Diabetes - Study B

We'll reach out to this number within 24 hrs